FibroScan Results Interpretation: Moderate Steatosis with Normal Liver Stiffness
Your FibroScan shows moderate hepatic steatosis (CAP 345 dB/m) with normal liver stiffness (5.4 kPa), indicating fatty liver without significant fibrosis.
CAP Score Analysis (345 dB/m)
Your CAP value of 345 dB/m indicates moderate to severe hepatic steatosis:
- Normal CAP range: 156-287 dB/m 1
- Mild steatosis (S1): ≥250 dB/m
- Moderate steatosis (S2): ≥299 dB/m
- Severe steatosis (S3): ≥327 dB/m 1
Your value of 345 dB/m places you in the moderate-to-severe steatosis category (between S2-S3), meaning 30-60% of your liver cells contain fat deposits 2. This is clinically significant and requires metabolic evaluation and lifestyle intervention.
Important caveat: If your BMI is ≥30 kg/m², CAP values tend to overestimate steatosis by approximately 20-30 dB/m 3. In obese patients, the optimal cutoff for moderate steatosis is 340 dB/m (versus 319 dB/m in non-obese patients), so your result may represent borderline moderate steatosis rather than severe if you are obese 3.
Liver Stiffness Measurement (5.4 kPa)
Your LSM of 5.4 kPa is within normal range:
- Normal liver stiffness: <5-5.5 kPa 4
- Significant fibrosis (F2): ≥8.2 kPa
- Advanced fibrosis (F3): ≥9.7 kPa
- Cirrhosis (F4): ≥13.6 kPa 2
This is reassuring—you have no evidence of significant liver fibrosis 5, 6. Your liver stiffness is essentially normal, indicating the fatty infiltration has not yet caused substantial scarring.
Clinical Implications
What This Means for Your Health
- You have metabolic dysfunction-associated steatotic liver disease (MASLD) with moderate steatosis but no fibrosis
- No immediate risk of cirrhosis or liver-related complications given the normal stiffness
- Cardiovascular and metabolic risks are your primary concern, not liver disease progression at this stage
Required Metabolic Workup
You must be evaluated for associated metabolic conditions 5:
- Type 2 diabetes screening: Fasting glucose, HbA1c, or oral glucose tolerance test
- Lipid panel: Total cholesterol, LDL, HDL, triglycerides
- Blood pressure assessment: Screen for hypertension
- Additional testing: Consider HOMA-IR for insulin resistance if not diabetic 5
- Screen for: Sleep apnea (if obese), polycystic ovary syndrome (if female)
Management Strategy
Lifestyle modification is your primary treatment 1, 5:
- Weight loss target: 7-10% body weight reduction can resolve steatosis and prevent progression
- Diet: Mediterranean diet pattern, reduce refined carbohydrates and saturated fats
- Exercise: 150-200 minutes/week of moderate-intensity aerobic activity plus resistance training
- Alcohol: Complete abstinence or minimal consumption (<1 drink/day for women, <2 for men)
Follow-Up Monitoring
Given your normal liver stiffness, you should:
- Repeat FibroScan in 2-3 years to monitor for fibrosis progression 5
- Calculate FIB-4 score annually (uses age, AST, ALT, platelets) as an inexpensive screening tool 6
- If FIB-4 >1.3 or LSM increases to >8 kPa on follow-up, refer to hepatology for advanced fibrosis evaluation 5, 6
When to Worry
Seek hepatology referral if you develop:
- Rising liver enzymes (AST/ALT) despite lifestyle changes
- FIB-4 score >1.3 on routine labs
- LSM >8 kPa on repeat FibroScan
- Clinical signs: jaundice, ascites, confusion, easy bruising
Key Pitfalls to Avoid
Do not ignore this result simply because fibrosis is absent. Moderate steatosis significantly increases your risk of:
- Type 2 diabetes development
- Cardiovascular events (heart attack, stroke)
- Progression to fibrotic liver disease over 5-10 years without intervention 5
Do not rely solely on liver enzymes (ALT/AST)—they are often normal in MASLD and do not correlate with steatosis severity 1, 7.
If you are obese (BMI ≥30), recognize that your CAP may slightly overestimate steatosis severity, but this does not change management—weight loss remains the cornerstone of treatment 3.